Company: Bristol Myers Squibb
Tags: pipeline, territory
BMS nivolumab/ipilimumab combo is holding its own in NSCLC despite Keytruda's dominance. The tumor mutational burden story is still working in the right accounts. My best oncologists appreciate having a mechanistically differentiated option for high TMB patients who aren't responding to anti-PD-1 monotherapy. Pull-through isn't easy — REMS requirements, monitoring, the immune-related AE counseling burden — but the oncologists who've had good outcomes with the combo are very loyal. If you're a new BMS rep going into this territory, know the TMB data cold. That's where the conversation lives.
44 upvotes · 0 comments